AI-Driven Healthcare Entrepreneurship: Transforming Clinical Practice Through Innovation, Access, and Affordability

Abstract

<ns3:p>Background Artificial intelligence (AI)–enabled ventures are reshaping clinical practice by extending diagnostic, triage, and telehealth capabilities in low- and middle-income countries (LMICs). Problem Despite rapid startup activity, rigorous evidence of tangible, equitable impact and cost-effectiveness in routine LMIC care remains limited; unresolved concerns include data privacy, algorithmic bias, interoperability, and governance. Research Objectives To assess how AI-driven healthcare entrepreneurship transforms access, quality, and affordability in clinical practice, and to surface enablers, barriers, and ethical implications. RQs (1) Where and how are entrepreneurial AI tools integrated into clinical workflows? (2) What measured effects on access, quality, efficiency, and costs are reported? (3) Which infrastructural, human-capital, and policy factors enable or impede adoption? (4) How are ethics—privacy, bias, explainability, accountability—addressed, and what frameworks are needed? Methodology Mixed-methods secondary synthesis combining a systematic literature review with NLP-assisted evidence mining (&gt;200 records; 87 deeply reviewed), triangulation of quantitative indicators (workforce, connectivity, investment) with qualitative case evidence (WHO and policy reports), interpreted through Diffusion of Innovation, Resource-Based View, and Principlism lenses. Results Startups deploy AI triage chatbots (as reflected in our aggregation of secondary sources described in §§3.2–3.3), portable imaging/diagnostics, telemedicine platforms, and supply-chain tools that can broaden coverage, speed diagnosis, and streamline workflows. Yet real-world evaluations are few; cost-effectiveness is context-dependent; adoption is uneven due to infrastructure gaps, limited/biased local data, interoperability frictions, and trust barriers. Success correlates with workflow fit, VRIO resources (data, talent, partnerships), local co-design, and human-in-the-loop, explainable models. Emerging evidence points to faster emergency logistics, expanded screening reach, and reduced wait times, but definitive outcome and economic endpoints remain scarce. Conclusion AI entrepreneurship can augment clinicians and improve service delivery but is not a panacea. Implication To realize equitable system-level gains, stakeholders should invest in digital public goods and representative datasets, build clinician and data-science capacity, operationalize WHO-aligned governance (privacy, bias audits, explainability, accountability), ensure reimbursement pathways beyond pilots, and scale through public-private and civil-society partnerships.</ns3:p>

Ähnliche Arbeiten